Rino Stocco
Saint-laurent, QC H4S2A1, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor.
Journal: Journal of medicinal chemistry
Published: May 16, 2025
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR.
Journal: Research square
Published: February 27, 2024
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR.
Journal: Nature communications
Published: February 07, 2024
Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500).
Journal: Journal of medicinal chemistry
Published: February 01, 2024
Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ.
Journal: Journal of medicinal chemistry
Published: September 20, 2022
Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.
Journal: Journal of medicinal chemistry
Published: July 26, 2022
RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors.
Journal: Molecular cancer therapeutics
Published: July 19, 2021
CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.
Journal: Nature
Published: April 20, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026